Send us a text

Why do we wait until we're severely unwell before seeking help? In this thought-provoking episode, I'm joined by Eva Papadopoulou, a mental health professional and expert in digital and AI-enabled healthcare solutions, to explore the transformative potential of preventative mental healthcare.

Eva reveals the stark reality of our current healthcare systems - less than 10% of budgets are allocated to prevention, despite evidence showing preventative approaches lead to better outcomes and cost savings. Using dental care as a compelling example, she illustrates how cultural shifts can transform how we approach healthcare. "We take care of our mind and body before it breaks, not after," Eva explains, offering a vision where mental wellbeing is nurtured proactively rather than repaired reactively.

We delve into key areas ripe for preventative intervention, including youth mental health (with most conditions developing before age 25) and workplace wellbeing, where burnout and absenteeism cost businesses billions annually. Technology emerges as a powerful enabler through apps, wearables, and AI systems that can detect early warning signs and deliver personalized support at scale. Eva emphasizes that successful health tech must be co-designed with users and integrated seamlessly into clinical pathways, while better health education is essential to help people interpret their health data meaningfully.

The conversation culminates with Eva's powerful vision for healthcare's future: shifting from short-term thinking to long-term investment that prioritizes prevention over crisis management. "Invest in the future instead of firefighting in the present," she urges, inviting listeners to imagine a society where understanding and maintaining mental wellbeing becomes as routine as brushing our teeth. Connect with Eva on LinkedIn to continue this important conversation about transforming healthcare through prevention.

________
Reach out to Ivanna Rosendal

Join the conversation on our LinkedIn page

Send us a text

Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.

• Current market uncertainty and investment challenges in biotech, especially for rare disease research
• Approximately two-thirds of clinical trial processes add no value and aren't required by regulations
• Many clinical trial failures occur not because drugs don't work but because trials can't recruit enough patients
• Companies often treat development phases as "islands" rather than planning for commercial success from the beginning
• Rare disease economics require greater efficiency since development costs must be recovered from much smaller patient populations
• Reviving shelved drug candidates represents a potentially valuable opportunity
• Patients should have greater input in trial design and outcome measures that matter to them
• Better communication between sponsors and regulators could significantly improve drug development

________
Reach out to Ivanna Rosendal

Join the conversation on our LinkedIn page

Send us a text

Jonathan Hill takes us on a fascinating journey through the cutting-edge world of DNA sequencing and its revolutionary potential for early disease detection. As both an academic professor at Brigham Young University and co-founder of Wasatch BioLabs, Hill shares how third-generation sequencing technologies are transforming our ability to identify diseases years before symptoms appear.

The conversation centers on a groundbreaking approach using native methylation calling—a method that identifies specific chemical modifications to DNA—to detect neurodegeneration in conditions like Alzheimer's and Parkinson's. Hill explains how these diseases damage the brain for up to a decade before symptoms emerge, creating a critical window where treatment could be most effective. By detecting the unique methylation signatures of dying neurons from cell-free DNA in the bloodstream, Wasatch BioLabs' technology aims to revolutionize diagnosis and treatment monitoring.

What makes this platform particularly powerful is its versatility. The same technology that identifies dying neurons can be adapted to detect signatures from other dying cell types, potentially offering early diagnostics for autoimmune diseases, various cancers, and other conditions—all from a simple blood draw.

Beyond the science, Hill reveals his passion for nurturing the next generation of biotech entrepreneurs. He's created a unique ecosystem at BYU where students with innovative ideas receive the mentorship, lab facilities, and business connections needed to translate academic discoveries into real-world applications. Drawing parallels to the tech boom of Silicon Valley, Hill emphasizes that biotech is experiencing its moment of explosive innovation, though with unique regulatory and infrastructure challenges.

The episode concludes with a thoughtful discussion on regulatory hurdles in life sciences and how streamlining these processes—while maintaining safety standards—could accelerate innovation and save countless lives. For anyone fascinated by the intersection of cutting-edge science, entrepreneurship, and healthcare transformation, this conversation offers an inspiring glimpse into the future of medicine.

________
Reach out to Ivanna Rosendal

Join the conversation on our LinkedIn page